Brexanolone Injection (Zulresso)

Zulresso (brexanolone) is covered only as a one‑time 60‑hour IV infusion (90 mcg/kg/hr) for adults ≥15 with moderate‑to‑severe postpartum depression with symptom onset in the third trimester or within 4 weeks after delivery, in patients ≤6 months postpartum who are not pregnant; coverage excludes onset outside that window, age <15, pregnancy, repeat dosing per postpartum period, and non‑FDA indications or mild depression. Coverage requires prescription by or consultation with a psychiatrist or OB‑GYN and documentation of diagnosis, symptom onset timing, postpartum/pregnancy status, age, dosing/infusion plan, and compliance with REMS/safety requirements.

"Zulresso is indicated for the treatment of postpartum depression (PPD) in adults."

Sign up to see full coverage criteria, indications, and limitations.